Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 8/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578073 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PPARAPPARGCTSKCTSS | |
| SCHEMBL703741 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2PPARAPPARGCTSKCTSS | |
| SCHEMBL1645172 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2PPARAPPARGCTSKCTSS | |
| SCHEMBL1645174 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2PPARAPPARGCTSKCTSS | |
| SCHEMBL1940630 | 0.87 | CTSK (0.46) | SMN1; SMN2PPARAPPARGCTSKCTSS | |
| SCHEMBL14031160 | 0.87 | CTSK (0.46) | SMN1; SMN2PPARAPPARGCTSKCTSS | |
| SCHEMBL1940631 | 0.87 | CTSK (0.46) | SMN1; SMN2PPARAPPARGCTSKCTSS | |
| SCHEMBL13925030 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2CTSKCTSSGAAKMT2A | |
| SCHEMBL13925029 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2CTSKCTSSGAAKMT2A | |
| SCHEMBL1943040 | 0.85 | CTSK (0.48) | SMN1; SMN2PPARAPPARGCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036708-A1 | Novel Process for the Preparation of Nonracemic Long Chain alpha-Amino Acid Derivatives | WUXI PHARMATECH CO., LTD. (CN) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036708-A1 | Novel Process for the Preparation of Nonracemic Long Chain alpha-Amino Acid Derivatives | AADAT, BCAT1, BCAT2 | SMN1; SMN2 3463/4885PPARA 1608/4885PPARG 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.